A Phase 1 Dose-Escalation Study of Advaxis (ADXS) NEO Expressing Personalized Tumor Antigens in Subjects With Metastatic Microsatellite Stable Colon Cancer, Metastatic Squamous Histology Head and Neck Cancer, and Metastatic Non-Small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs ADXS NEO (Primary)
- Indications Colon cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms NEO
- Sponsors Advaxis
- 11 Sep 2017 According to an Advaxis media release, the first patient is expected to be dosed in 1H 2018.
- 28 Aug 2017 Status changed from planning to not yet recruiting.
- 13 Jun 2017 According to an Advaxis media release, the FDA has accepted the ADXS-NEO IND in March 2017.